ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACON ACLARION, INC

Post-Mkt 03-10 17:34:23 EDT

3.28

+0.02

+0.61%

盘后3.26

-0.02-0.61%

17:10 EDT

High3.52	Low3.21	Vol160.50K
Open3.21	D1 Closing3.26	Amplitude9.51%
Mkt Cap3.46M	Tradable Cap3.46M	Total Shares1.05M
T/O542.56K	T/O Rate15.22%	Tradable Shares1.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACON","market":"US","secType":"STK","nameCN":"ACLARION, INC","latestPrice":3.28,"timestamp":1773172800000,"preClose":3.26,"halted":0,"volume":160495,"hourTrading":{"tag":"盘后","latestPrice":3.26,"preClose":3.28,"latestTime":"17:10 EDT","volume":215,"amount":700.1800079999999,"timestamp":1773177057978,"change":-0.02,"changeRate":-0.006098,"amplitude":0.015244},"delay":0,"changeRate":0.0061349693251533804,"floatShares":1054300,"shares":1054400,"eps":-1597.95,"marketStatus":"Post-Mkt","change":0.02,"latestTime":"03-10 17:34:23 EDT","open":3.21,"high":3.52,"low":3.21,"amount":542564.806843,"amplitude":0.095092,"askPrice":3.49,"askSize":1,"bidPrice":3.15,"bidSize":26,"shortable":3,"etf":0,"ttmEps":-1597.95,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773187200000},"marketStatusCode":4,"adr":0,"listingDate":1650600000000,"exchange":"NASDAQ","adjPreClose":3.26,"preHourTrading":{"tag":"盘前","latestPrice":3.05,"preClose":3.26,"latestTime":"09:26 EDT","volume":191,"amount":593.6949455,"timestamp":1773149178789,"change":-0.21,"changeRate":-0.064417,"amplitude":0.067485},"postHourTrading":{"tag":"盘后","latestPrice":3.26,"preClose":3.28,"latestTime":"17:10 EDT","volume":215,"amount":700.1800079999999,"timestamp":1773177057978,"change":-0.02,"changeRate":-0.006098,"amplitude":0.015244},"volumeRatio":1.622568},"requestUrl":"/m/hq/s/ACON/tweets","defaultTab":"tweets","newsList":[{"id":"2609756376","title":"Aclarion Inc - Has Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2609756376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609756376?lang=en_us&edition=fundamental","pubTime":"2026-02-05 19:06","pubTimestamp":1770289574,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nFWN3Z10SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACON","BK4167","ACONW"],"gpt_icon":0},{"id":"2608882792","title":"Aclarion schließt Vereinbarung mit Source Healthcare zur Nutzung von Nociscan","url":"https://stock-news.laohu8.com/highlight/detail?id=2608882792","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608882792?lang=en_us&edition=fundamental","pubTime":"2026-02-03 19:00","pubTimestamp":1770116457,"startTime":"0","endTime":"0","summary":"Aclarion Inc. hat eine Vereinbarung mit Source Healthcare, einer orthopdischen und regenerativen Klinik in Los Angeles, geschlossen. Ziel ist die Erweiterung der Verfügbarkeit der Nociscan-Lsung zur Identifikation von chronischen Rückenschmerzen. Die Zusammenarbeit soll die Generierung von Real-World-Evidenz unterstützen und die Nutzung von Nociscan im Vergleich zur ansthetischen Diskographie untersuchen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via GlobeNewswire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL61Hy2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU2210149790.SGD","SG9999014013.SGD","SG9999014039.USD","BK4588","LU0314104364.USD","BK4167","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","ACON","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014021.USD","NDAQ","IE00B64PRP62.GBP","BK4585"],"gpt_icon":0},{"id":"2603635775","title":"Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout","url":"https://stock-news.laohu8.com/highlight/detail?id=2603635775","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603635775?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:51","pubTimestamp":1768319460,"startTime":"0","endTime":"0","summary":"Aclarion, Inc. (NASDAQ: ACON) closed a $10.4 million financing at $5.18/share, boosting balance sheet & extending cash runway to 2028.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/13/Ipo-Initial-Public-Offering--Business-Ma.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/13/Ipo-Initial-Public-Offering--Business-Ma.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49879642/aclarion-raises-10-4-million-sharpens-focus-on-nociscan-rollout","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49879642/aclarion-raises-10-4-million-sharpens-focus-on-nociscan-rollout","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2603687704","title":"BRIEF-Aclarion Inc - Extends Cash Runway Into 2028 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603687704","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603687704?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:07","pubTimestamp":1768313279,"startTime":"0","endTime":"0","summary":"BRIEF-Aclarion Inc - Extends Cash Runway Into 2028 - SEC FilingJan 13 (Reuters) - Aclarion Inc ACON.O:ACLARION INC - EXTENDS CASH RUNWAY INTO 2028 - SEC FILINGFurther company coverage: ACON.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE10N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"gpt_icon":0},{"id":"2601395854","title":"Aclarion Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2601395854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601395854?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:00","pubTimestamp":1767884434,"startTime":"0","endTime":"0","summary":"09:59 EST Aclarion (ACON) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclarion-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclarion-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2601622673","title":"Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars","url":"https://stock-news.laohu8.com/highlight/detail?id=2601622673","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601622673?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:29","pubTimestamp":1767878940,"startTime":"0","endTime":"0","summary":"Aclarion Inc. (NASDAQ: ACON) provided a corporate update on Thursday, reporting strong commercial momentum.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/08/Muscular-Man-Suffering-From-Back-And-Nec.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/08/Muscular-Man-Suffering-From-Back-And-Nec.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49781264/aclarions-ai-back-pain-tech-sees-114-surge-in-demand-stock-soars","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/01/49781264/aclarions-ai-back-pain-tech-sees-114-surge-in-demand-stock-soars","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2601548363","title":"Aclarion Launches CLARITY Trial to Advance Nociscan for Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2601548363","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601548363?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:00","pubTimestamp":1767870048,"startTime":"0","endTime":"0","summary":"Aclarion Inc. has announced the launch of the CLARITY trial in 2025, with seven activated sites. The company aims to enroll approximately 25% of patients in the trial by the end of the second quarter of 2026, with the first internal readout on interim data anticipated in the third quarter of 2026. The CLARITY trial is part of Aclarion’s strategy to advance clinical validation for its Nociscan platform, a cloud-based solution utilizing MR spectroscopy and augmented intelligence to identify the location of chronic low back pain. Results from this trial have not yet been presented; interim data is expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL5gwfj1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","ACON","BK4585","SG9999014039.USD","SG9999014005.SGD","BK4167","LU2210150020.SGD"],"gpt_icon":0},{"id":"2601635553","title":"Aclarion Inc - Aims to Enroll 25% in Clarity Trial by Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601635553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601635553?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:00","pubTimestamp":1767870001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA5QWL3R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACONW","ACON","BK4167"],"gpt_icon":0},{"id":"2601363849","title":"Aclarion Provides 2025 Update and 2026 Corporate Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601363849?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:00","pubTimestamp":1767870001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA5QWL3R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACON","ACONW","BK4167"],"gpt_icon":0},{"id":"2601363574","title":"Aclarion Inc - Cash Resources Sufficient to Fund Operations Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601363574?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:00","pubTimestamp":1767870001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA5QWL3R:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACON","ACONW","BK4167"],"gpt_icon":0},{"id":"2601891509","title":"BRIEF-Aclarion Announces First Patient Enrollments At Two Additional Clarity Trial Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2601891509","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601891509?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:40","pubTimestamp":1767699649,"startTime":"0","endTime":"0","summary":"BRIEF-Aclarion Announces First Patient Enrollments At Two Additional Clarity Trial Sites Jan 6 (Reuters) - Aclarion Inc ACON.O:ACLARION ANNOUNCES FIRST PATIENT ENROLLMENTS AT TWO ADDITIONAL CLARITY TR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y61A2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACONW","BK4167","ACON"],"gpt_icon":0},{"id":"2601998088","title":"Aclarion Inc - First Interim Data Readout Expected in 3Q 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601998088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601998088?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:01","pubTimestamp":1767697292,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y61A2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACONW","ACON","BK4167"],"gpt_icon":0},{"id":"2601993338","title":"Aclarion Inc - Acclarion Targets Full Enrollmentof 300 Patients by Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2601993338","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601993338?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:01","pubTimestamp":1767697292,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y61A2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACONW","BK4167","ACON"],"gpt_icon":0},{"id":"2601807899","title":"Aclarion Announces First Patient Enrollments at Two Additional Clarity Trial Sites and Provides Guidance on Expected Availability of Initial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2601807899","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601807899?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:01","pubTimestamp":1767697292,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y61A2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2601899352","title":"Aclarion Launches CLARITY Trial with First Patients Enrolled at Leading Spine Centers","url":"https://stock-news.laohu8.com/highlight/detail?id=2601899352","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601899352?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:00","pubTimestamp":1767697252,"startTime":"0","endTime":"0","summary":"Aclarion Inc. has announced the enrollment of the first patients at Northwestern Medicine and Scripps Health for its pivotal CLARITY trial, which is designed to evaluate the company's technology for identifying the source of chronic low back pain. Seven leading U.S. spine centers are now participating in the study. The company aims to enroll approximately 25% of patients by the end of the second quarter of 2026, with an initial interim data readout expected after the first cohort completes a three-month follow-up visit in the third quarter of 2026. Results from the trial have not yet been presented; additional patient data will be incorporated on a rolling basis until enrollment is complete or until statistically significant results are observed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL3mB8gj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","SG9999014005.SGD","BK4588","LU2210150020.SGD","BK4167","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","LU2210149790.SGD","NDAQ","ACON","SG9999014021.USD","BK4112"],"gpt_icon":0},{"id":"2588888882","title":"Aclarion Nociscan Study Published in Leading Spine Surgery Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2588888882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588888882?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:11","pubTimestamp":1764853914,"startTime":"0","endTime":"0","summary":"Aclarion Inc. has announced the publication of a featured article on its Nociscan technology in the Special Pain Issue of the International Journal of Spine Surgery . The article highlights a successful clinical case in which Nociscan, a noninvasive SaaS platform, was used alongside traditional MRI to more accurately identify the source of chronic low back pain in a patient. As a result, the surgeon was able to limit surgical intervention to the affected disc, leading to the elimination of the patient's pain and a full return to an active lifestyle. These results, which strengthen the clinical evidence supporting Nociscan, have already been published in advance online by the IJSS.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4p81Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2588505348","title":"Press Release: Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588505348","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588505348?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680400,"startTime":"0","endTime":"0","summary":"-- Proven commercial leader with 20+ years of experience driving revenue. growth and market adoption for early-stage and high-growth MedTech. Jason is a proven commercial leader with more than 20 years of experience accelerating revenue growth and building high-performing teams for high-growth MedTech companies, including roles at Relievant Medsystems , Kyphon , and Intrinsic Therapeutics. His background in successfully launching breakthrough technologies and establishing new market categories across spine, orthopedics, and pain management makes him exceptionally well-positioned to drive the adoption of Nociscan in the Eastern U.S.\"Jason's hire represents another significant commercial milestone for the Company,\" said Brent Ness, CEO of Aclarion. \"The growing demand for Nociscan through real-world evidence trials, and the national CLARITY randomized controlled trial, necessitates additional commercial resources in the densely populated Eastern U.S. Jason brings the critical early-stage","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EML","ACON","BK4161","BK4167"],"gpt_icon":0},{"id":"2588570518","title":"Aclarion CEO Brent Ness Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588570518","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588570518?lang=en_us&edition=fundamental","pubTime":"2025-12-02 06:00","pubTimestamp":1764626430,"startTime":"0","endTime":"0","summary":"Brent Ness, Chief Executive Officer and Director of Aclarion Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL6RbYM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aclarion CEO Brent Ness Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2584154138","title":"Aclarion Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584154138","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584154138?lang=en_us&edition=fundamental","pubTime":"2025-11-20 18:51","pubTimestamp":1763635860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2025 05:51 ET (10:51 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"gpt_icon":0},{"id":"2582374728","title":"Aclarion Q3 EPS $(2.93) Misses $(2.62) Estimate, Sales $18.942K Miss $40.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374728","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374728?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:52","pubTimestamp":1762955533,"startTime":"0","endTime":"0","summary":"Aclarion (NASDAQ:ACON) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.62) by 11.83 percent. This is a 99.8 percent increase over losses of $(1.50 thousand) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48801864/aclarion-q3-eps-2-93-misses-2-62-estimate-sales-18-942k-miss-40-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclarion.com","stockEarnings":[{"period":"1week","weight":0.1399},{"period":"1month","weight":0.1855},{"period":"3month","weight":-0.466},{"period":"6month","weight":-0.5415},{"period":"1year","weight":-0.9125},{"period":"ytd","weight":-0.2913}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.04},{"period":"1year","weight":0.1777},{"period":"ytd","weight":-0.0054}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.316115},{"month":2,"riseRate":0.25,"avgChangeRate":-0.352706},{"month":3,"riseRate":0.25,"avgChangeRate":-0.24301},{"month":4,"riseRate":0,"avgChangeRate":-0.174468},{"month":5,"riseRate":0.5,"avgChangeRate":0.044825},{"month":6,"riseRate":0.25,"avgChangeRate":-0.115199},{"month":7,"riseRate":0.5,"avgChangeRate":-0.021585},{"month":8,"riseRate":0.5,"avgChangeRate":-0.066272},{"month":9,"riseRate":0.25,"avgChangeRate":-0.18466},{"month":10,"riseRate":1,"avgChangeRate":0.110748},{"month":11,"riseRate":0,"avgChangeRate":-0.1724},{"month":12,"riseRate":0,"avgChangeRate":-0.242895}],"exchange":"NASDAQ","name":"ACLARION, INC","nameEN":"ACLARION, INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACLARION, INC(ACON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACLARION, INC,ACON,ACLARION, INC股票,ACLARION, INC股票老虎,ACLARION, INC股票老虎国际,ACLARION, INC行情,ACLARION, INC股票行情,ACLARION, INC股价,ACLARION, INC股市,ACLARION, INC股票价格,ACLARION, INC股票交易,ACLARION, INC股票购买,ACLARION, INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACLARION, INC(ACON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}